Formerly known as Assogenerici, Egualia is an Italian industry association representing generics and biosimilar companies. Michele Uda, its director-general, speaks about the industry’s impressive response to the COVID-19 pandemic and analyses the potential impact of recent changes to Italy’s pricing and reimbursement system.
The pandemic showed us the importance of putting patients at the centre, but we must ensure that they continue having access to medicines. If we all aim in that direction, the public-private partnerships created during the pandemic will endure, benefiting patients
